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Purpose. To observe the protecting eﬀects and mechanisms of Baicalin and Octreotide on heart injury in rats with severe acute
pancreatitis (SAP). Methods. The SAP rat models were randomly divided into the model group, Baicalin-treated group, Octreotide
treated group, and sham operation group. The contents of some inﬂammatory indexes in blood were determined. The rat mortal-
ity, pathological changes of heart, the changes of NF-κB, P-Selectin, Bax, Bcl-2, and Caspase-3 protein expression levels as well as
apoptotic index were observed in all groups, respectively, at 3 hours, 6 hours, and 12 hours after operation. Results: The survival
rate of model group was less than treated groups at 12 hours, diﬀerence was signiﬁcant. The contents of some inﬂammatory in-
dexes of the treated groups were lower than those of the model group to various degrees at diﬀerent time points. The pathological
myocardial changes under light microscope were milder in treated groups than in model group. The changes of NF-κB, P-Selectin,
Bax, Bcl-2, and Caspase-3 protein expression levels in all groups were diﬀerent. There was only a case of myocardial cell apoptosis
in an Octreotide-treated group at 6 hours. Conclusion. Baicalin and Octreotide have protecting eﬀects on heart injury of rats with
SAP.
Copyright © 2007 Zhang Xiping et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
As a common acute abdomen in the clinic, severe acutepan-
creatitis (SAP) has acute onset and dangerous progression.
SAP can easily cause nonpancreas organ injuries, and lead
to multiple organ dysfunction (MODS). Its features include
dangerous onset, rapid progression and evolvement, mul-
tiple complications, great harm, and high mortality [1–4].
The studies on heart injury are relatively few among non-
pancreas organ injuries; but the cardiovascular decompen-
sation is one of SAP complications with highest mortality.
Theclinicalexaminationsoftenﬁndelectrocardiographicab-
normality [5, 6], signiﬁcant change of troponin [7–11], and
myocardial zymogram [12, 13]. Its major complicated heart
diseases include heart function change, arrhythmia, cardiac
shock, toxic myocarditis, pericarditis, myocardial infarction,
and so forth. However, there are few drugs to eﬀectively treat
such patients.
In “Qing Yi Tang” which is a representative prescrip-
tion of Chinese medicine for SAP treatment, the enormous
clinical practices also suggest its sound therapeutic eﬀects
on SAP. Scutellaria baicalensis georgi is a main material in
“Qing Yi Tang” while Baicalin (monomer) is its main ac-
tive constituent. The intravenous administration with very
low price can overcome the shortcomings of oral adminis-
tration of “Qing Yi Tang” including poor absorption and in-
convenience. The vitro experiments of Baicalin have proved
that it has antibacteria, antivirus, and antiinﬂammation ac-
tivities. It also can inhibit platelet aggregation and eliminate
oxygen free radicals. In animal experiments, Baicalin with
choleretic eﬀectcan can relieve fever, inhibit the thrombin-
induced transforming process from ﬁbrin to ﬁbrin, reduce
endotoxin generation, and treat and prevent endotoxemia-
inducedDIC.Inaddition,theinitialmetaboliteofBaicalinin
body is baicalein that can more eﬀectively inhibit pancreatin.
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during SAP onset. Its many eﬀects are similar to those of So-
matostatin and its analogues such as Octreotide, but it has a
broader application range. It is theoretically feasible to use it
for SAP treatment.
As a commonly used drug to treat SAP, Octreotide can
alleviate pathological changes of pancreas, reduce ascites,
hemodiastase, and lipase, restore pancreatic tissue, inhibit
secretion of gastrointestinal hormone and gastric acid, re-
lieve smooth muscle spasm, inhibit local inﬂammatory re-
actions, improve pancreas microcirculation, and so forth.
Meanwhile, it has defects such as expensive price, short half-
life, inconvenient administration, and that it cannot be pop-
ularized in remote areas. Therefore, looking for its substitute
with low price and good eﬀects is a realistic choice. Baicalin
haspharmacologicactionssimilartothoseofOctreotide.Itis
alsocheapandhasfewsideeﬀectsandalonghalf-life.There-
fore, it is a promising SAP treating medicine, and has higher
research value.
Presently,therehasnot beenanystudy report onBaicalin
treatment of SAP domestically and internationally. This ex-
periment has established the rat SAP model, utilized the
tissue microarrays [14], discussed the protecting eﬀects of
Baicalin on heart injury in rats with SAP, and compared its
eﬀects with those of Octreotide in order to provide the reli-
able basis for Baicalin treatment of SAP.
2. MATERIALS AND METHODS
2.1. Materials
Clean grade healthy male Sprague-Dawley (SD) rat 250–
300g body weight purchased from the Experimental
Animal Center of Medical School, Zhejiang University
(Hangzhou, China). Sodium taurocholate and sodium pen-
tobarbital purchased from Sigma-Aldrich (Mo, USA). Oc-
treotide purchased from Novartis (Basel, Switzerland); 5%
Baicalin injection (China national invention patent number
ZL200310122673.6) prepared by Z. Xiping with 305mmol/L
osmotic pressure. The full automatic biochemical analyzer
was used to determine the plasma amylase level (U/L).
Plasma endotoxin tachypleus amebocyte lysate kit was pur-
chased from Shanghai Yihua Medical Science and Technol-
ogy Corporation (Institute of Medical Analysis in Shang-
hai, China). The calculation unit for content is EU/mL. The
serum nitrogen monoxidum (NO), malonaldehyde (MDA),
superoxide dismutase (SOD) kits were all purchased from
Nanjing Jiancheng Bioengineering Research Institute (Nan-
jing, China). The calculation units for content are, respec-
tively, μmol/L, nmol/mL, and U/mL. The TNF-α ELISA
kit was purchased from Jingmei Bioengineering Corpora-
tion (Shengzhen, China). The calculation unit for content
is pg/mL (ng/L). The serum secretory phospholipase A2 en-
zyme Assay ELA kit (PLA2) was purchased from RδDs y s -
tem Ins and the calculation unit for content is U/mL. The
serum Endothelin-1 ELA kit (ET-1) was purchased from
Cayman chemical company (Mich, USA) (catalog number:
583151)andthecalculationunitforcontentisng/L(pg/mL).
The NF-κB, Bax, Bcl-2, and P-Selectinantibody were pur-
chased from Santa Cruz Company (Calif, USA). Caspase-3
antibody was purchased from NeoMarkers Company (Calif,
USA),DNAnickinsituend-labeling(TUNEL)kitpurchased
from Takara BIO INC (Shiga, Japan). The above determina-
tions were all operated according to the instructions of the
kits.
2.2. Methods
2.2.1. Animalgrouping
The improved Aho method was adopted to prepare SAP
rat models. The 135 SAP rat models after being prepared
were randomly divided into model group, Baicalin-treated
group, and Octreotide-treated group with 45 rats in each
group; other 45 were selected to be sham operation group,
which only received abdomen opening surgery. The above-
mentioned groups were then randomly divided into 3 hour,
6h o u r ,a n d1 2h o u rg r o u p sw i t h1 5r a t si ne a c hg r o u p ,a n d
observation made, respectively, at diﬀerent points after oper-
ation [14–16].
2.2.2. Preparationmethodsofanimalmodels
The rats were anesthetized by intraperitoneal injection of
2% sodium pentobarbital (0.25mL/100g) after which the
rats are laid and ﬁxed, routine shaving, disinfection, and
draping are performed, First established the right exter-
nal jugular vein transfusion passage used the microinfu-
sion pump for continuous transfusion (1mL/h/100g) and
then used 3.5% sodium taurocholate to prepare SAP model
[14–16].
Dosageandmethods[14–16]:
(1) Baicalin-treated group: The animal experiments of 5%
Baicalin injection have been completed including the acute
toxicity test and SAP rat treatment by small, middle, and
largedose.Thelargedosecanachievethebesttherapeuticef-
fect (dose is 10mg/h/100g) and the dosage referred to the re-
sultofthepreviouspreliminaryexperiment.10minutesafter
successfulmodeling,Baicalin-treatedgroupwasﬁrstinjected
with 5% Baicalin injection 10mg/100g via external jugular
vein passage followed by continuous intravenous adminis-
tration (10mg/h/100g) by microinfusion pump; Octreotide-
treated group was ﬁrst injected Octreotide 0.2ug/100g via
external jugular vein passage followed by continuous intra-
venous transfusion (10mg/h/100g) by microinfusion pump
at a transfusion speed of 0.2ug/h/100g. All above dosages
have been proved as eﬀective dosages in the previous prelim-
inary experiment.
(2) Sham operation group and model group: Both of
them were injected saline of equivalent volume at the cor-
responding time points after operation.
Tissue microarrays of heart [17] are prepared as follows.
2.3. OBSERVATIONINDEXES
(1) Survival rate: Examined the rat mortality at 3 hours, 6
hours, and 12 hours after operation and calculated the sur-
vival, observed the gross changes of heart.Zhang Xiping et al. 3
(2) After mercy killing, rats anesthetized by sodium pen-
tobarbital in batches, collected the intestinal samples from
heart, ﬁxed them according to the related requirements, and
observed the pathological changes of heart after HE staining.
(3) The contents of plasma amylase and endotoxin,
serum NO, SOD, MDA, TNF-α,P L A 2,a n dE T - 1w e r ed e t e r -
mined via blood sampling from heart.
(4) NF-κB, P-Selectin, Caspase-3, Bax, and Bcl-2protein
expression: Applied tissue microarrays to prepare heart sec-
tions, adopted SP method for immunohistochemical stain-
ing, and observed the NF-κB, P-Selectin, Caspase-3, Bax,
and Bcl-2 protein expression of heart tissue under light mi-
croscope, respectively, and carried out the comprehensive
assessment according to the positive cell percentage: posi-
tive cell count <10% means (—); positive cell count 10–20%
means (+); positive cell count 20–50% means (++); positive
cell count >50% means (+++).
(5) Apoptotic index: Applied the tissue microarrays to
preparetheheartmicroarraysectionsandadoptedDNAnick
in situ end-labeling (TUNEL) technology for staining. Ob-
served the intestinal mucosa apoptotic cells and calculated
apoptotic index, respectively.
Statisticalmethods:
The values were presented as mean and standard deviation
for normal distribution variables or median and quartile
range for highly skewed variables. The signiﬁcance of diﬀer-
ences among the four groups was tested using the Kruskal-
Wallis test for highly skewed data and analysis of variance
(ANOVA) for normal distribution data. Multiple compar-
isons were subjected to Bonﬀeroni correction test. The chi-
square test was used to evaluate equality of frequencies for
discrete variables. Correlations were tested using the Spear-
manrankcorrelationcoeﬃcients.APvaluelessthanorequal
to .05 was considered statistical signiﬁcant, and all statisti-
cal analyses were conducted using SPSS version 11.5 for win-
dows.
3. RESULTS
Survivalrate:
Themortalitiesofmodelgroupwere,respectively,0%(0/15),
13.33% (2/15), and 33.33% (5/15) at 3 hours, 6 hours, and
12 hours; all the mortalities of Baicalin-treated group and
Octreotide-treated group were 0% at diﬀerent time points.
The whole sham operation group survived at diﬀerent time
points. The survival of model group was 66.67% (10/15) at
12 hours while the survivals of both Baicalin-treated group
and Octreotide-treated group were 100% at 12 hours, indi-
cating marked diﬀerence (P < .05) [14–16].
Comparisonofplasmaamylasecontentinallgroups:
The plasma amylase content of model group and two treated
groups signiﬁcantly exceeded that of sham operation group
at diﬀerent time points (P < .001). There was no marked
diﬀerence between Baicalin-treated group and Octreotide-
treatedgroupatdiﬀerent time points (P > .05). Although the
plasma amylase content of Baicalin-treated group was lower
than that of model group at diﬀerent time points, Baicalin-
treated group was signiﬁcantly less than model group at 3
hours (P < .05). There was no marked diﬀerence between
Baicalin-treated group and model group at 6 hours and 12
hours (P > .05). Octreotide-treated group was signiﬁcantly
less than model group at 6 hours (P < .05). There was
no marked diﬀerence between Octreotide-treated group and
model group at 3 hours and 12 hours (P > .05), see Table 1
[15, 16].
Comparisonofplasmaendotoxincontentsinallgroups:
The model group and treated groups were signiﬁcantly
higher than the sham operation group at all time points
(P < .001), no marked diﬀerence between the Baicalin-
treated group and Octreotide-treated group at 6 hours and
12 hours (P > .05). Both the Baicalin-treated group and
Octreotide-treated group were signiﬁcantly lower than the
modelgroupat3hours(P<.001),theBaicalin-treatedgroup
was signiﬁcantly lower than the Octreotide-treated group (P
< .01). The Baicalin-treated group was signiﬁcantly lower
than the model group at 6 hours (P < .05), the Octreotide-
treated group was signiﬁcantly lower than the model group
(P =.001).TheBaicalin-treatedgroupwassigniﬁcantlylower
than the model group at 12 hours (P < .001), the Octreotide-
treated group was signiﬁcantly lower than the model group
(P < .01), see Table 1.
ComparisonofserumNOcontentinallgroups:
Modelgroup,Baicalin-treatedgroup,andOctreotide-treated
group all signiﬁcantly exceeded sham operation group at dif-
ferent time points (P < .001). At 3 hours and 12 hours,
Baicalin-treated group was signiﬁcantly less than model
group (P < .05), Octreotide-treated group was signiﬁcantly
lessthanmodelgroup(P <.01).Therewasno markeddiﬀer-
ence between Baicalin-treated group and Octreotide-treated
group at diﬀerent time points (P > .05), see Table 1.
Comparisonofserummalonaldehyde(MDA)
contentinallgroups:
The model group, Baicalin-treated group and Octreotide-
treated group all signiﬁcantly exceeded the sham operation
group at diﬀerent time points (P < .05). Baicalin-treated
group was signiﬁcantly less than the model group (P < .01).
Octreotide-treated group was signiﬁcantly less than the
model group at 6 hours and 12 hours (P < .05). Baicalin-
treated group was signiﬁcantly less than Octreotide-treated
group at 12 hours (P < .05), see Table 1.
ComparisonofserumSODcontentsinallgroups:
Model group, Baicalin-treated group and Octreotide-treated
groupwereallsigniﬁcantlylowerthanshamoperationgroup
at diﬀerent time points (P < .01), and Octreotide-treated
group was signiﬁcantly higher than model group (P < .01).4 Mediators of Inﬂammation
Table 1: Comparison of diﬀerent indexes level in blood (M(QR))
Indexes Time point Sham operation group Model group Baicalin-treated group Octreotide-treated group
Amylase (U/L)
3h 1582.00(284.00) 5303.00(1373.00) 4342.00(1496.00) 5419.00(1670.00)
6h 1769.00(362.00) 6276.00(1029.00) 5130.00(1591.00) 5058.00(1314.00)
12h 1618.00(302.00) 7537.50 (2933.50) 5571.00(2307.00) 6531.00(2280.00)
Endotoxin (pg/mL)
3h 0.016(0.005) 0.053(0.029) 0.027(0.005) 0.033(0.006)
6h 0.016(0.010) 0.059(0.037) 0.039(0.019) 0.031(0.010)
12h 0.014(0.015) 0.060(0.022) 0.034(0.015) 0.042(0.014)
NO (pg/mL)
3h 7.500(5.00) 65.00(7.50) 57.50(22.50) 52.50(15.00)
6h 7.500(5.00) 62.50(38.75) 47.50(37.50) 57.50(15.00)
12h 10.00(5.00) 74.10(26.15) 57.50(27.50) 45.00(12.50)
MDA (nmol/mL)
3h 9.90(9.90) 36.30(13.40) 21.90(13.45) 29.60(18.60)
6h 16.50(13.20) 39.70(9.90) 23.80(14.60) 33.00(9.90)
12h 16.50(13.20) 54.35(19.00) 36.00(11.60) 40.30(16.80)
TNF-α (pg/mL)
3h 3.90(3.20) 41.44(37.72) 44.93(45.8420) 39.30(30.60)
6h 4.00(1.70) 92.15(23.12) 65.10(27.51) 47.60(16.50)
12h 5.30(3.00) 65.02(26.81) 47.65(25.52) 54.50(41.40)
ET-1 (pg/mL)
3h 15.293(4.231) 24.745(1.011) 19.635(6.065) 16.827(3.775)
6h 16.275(3.180) 25.625(7.973) 16.226(3.174) 14.855(5.747)
12h 14.173(2.556) 24.725(3.759) 18.625(5.780) 15.185(1.761)
Baicalin-treated group was signiﬁcantly higher than model
group at 6 hours and 12 hours (P < .01), and Octreotide-
treated group was signiﬁcantly higher than Baicalin-treated
group (P < .01), see Table 1.
ComparisonofserumTNF-αcontentinallgroups:
Model group and treated groups signiﬁcantly exceeded sham
operation group at diﬀerent time points (P < .001). There
was no marked diﬀerence among model group, Baicalin-
treated group and Octreotide-treated group at 3 hours and
12 hours (P > .05). At 6 hours both Baicalin-treated group
and Octreotide-treated group were signiﬁcantly less than
model group (P < .001). Octreotide-treated group was sig-
niﬁcantly less than Baicalin-treated group (P < .01), see
Table 1.
ComparisonofserumET-1contentsinallgroups:
Model group was signiﬁcantly higher than sham operation
group at all time points (P < .001). At all time points,
Baicalin-treated group was signiﬁcantly lower than model
group (P < .001), and Octreotide-treated group was sig-
niﬁcantly lower than model group (P < .001). Octreotide-
treated group was signiﬁcantly lower than Baicalin-treated
group at 3 hours and 12 hours (P < .01). At 3 hours,
Baicalin-treated group was signiﬁcantly higher than sham
operation group (P < .01), and Octreotide-treated group was
not signiﬁcantly diﬀerent from sham operation group. At
6 hours, there was no marked diﬀerence between Baicalin-
treated group or Octreotide-treated group and sham opera-
tion group (P > .05), or between Baicalin-treated group and
Octreotide-treated group (P > .05). At 12 hours, Octreotide-
treated group and sham operation group had no marked dif-
ference (P > .05), and Baicalin-treated group was as signif-
icantly higher than sham operation group (P < .001), see
Table 1.
ComparisonofserumPLA2 contentinallgroups:
Model group and treated groups signiﬁcantly exceeded sham
operation group at diﬀerent time points (P <. 001). At
3 hours, Baicalin-treated group was signiﬁcantly less than
model group (P < .01), there was no marked diﬀerence be-
t w e e nO c t r e o t i d e - t r e a t e dg r o u pa n dm o d e lg r o u p( P > .05),
Baicalin-treatedgroupwassigniﬁcantlylessthanOctreotide-
treated group (P < .01). At 6 hours and 12 hours, Baicalin-
treated group was signiﬁcantly less than model group (P <
.001), Octreotide-treated group was signiﬁcantly less than
model group (P < .001). At 6 hours, there was no marked
diﬀerence between Baicalin-treated group and Octreotide-
treated group (P > .05). At 12 hours, Octreotide-treated
group was signiﬁcantly less than Baicalin-treated group (P
< .001), see Table 2.
4. PATHOLOGICAL CHANGES OF
MYOCARDIAL TISSUE
Grosschanges:
Normal-appearing and no marked appearance change were
seen in all groups.
Changesunderlightmicroscope:
The cardiac muscle ﬁberwas normal in sham operation
group,andnocardiacmuscleﬁberabnormalitywasfoundin
most other groups. In model group, 2, 1, 1 case of granularZhang Xiping et al. 5
Table 2: Comparison of serum PLA2 content in all groups (X ±S).
Groups 3 hours 6 hours 12 hours
Sham operation group 14.6170 ± 3.0160 17.4860 ±3.8205 19.0187 ±5.0660
Model group 76.0941 ±16.7036 101.4595 ±14.6662 105.3285 ±18.1015
Baicalin-treated group 56.2481 ±22.4331 67.9088 ±20.6117 66.8585 ±22.0971
Octreotide-treated group 74.3729 ±19.9352 63.1289 ±26.3061 53.6335 ±12.2774
Figure 1: Octreotide-treated group-12h NF-κB × 200 (negtive ex-
pression).
or dissolved carcoplasm of rat cardiac muscle ﬁber occurred,
respectively, at 3 hours, 6 hours, and 12 hours. At 6 hours,
there were 2 cases of few inﬂammatory cell inﬁltrations in
myocardial interstitium. At 12 hours, there was 1 case of few
inﬂammatory cell inﬁltrations in epicardium. In Baicalin-
treated group, 2 cases of carcoplasm aggregation occurred
at 12 hours; 1, 1, 2 cases of few inﬂammatory cell inﬁltra-
tions occurred in rat myocardial interstitium, respectively, at
3 hours, 6 hours, and 12 hours. In Octreotide-treated group,
1 case of carcoplasm aggregation occurred at 12 hours; few
inﬂammatory cell inﬁltrations occurred in rat myocardial
interstitium only once at diﬀerent time points. The patho-
logical myocardial changes were milder in Baicalin-treated
group and Octreotide-treated group than in model group,
a n dO c t r e o t i d e - t r e a t e dg r o u ph a db e t t e rt h e r a p e u t i ce ﬀects.
Comparison of NF-κB protein expression levels of my-
ocardial tissue in all groups: The NF-κB protein expression
was negative in all groups which showed no marked diﬀer-
ence (P > .05), see Figure 1.
ComparisonofmyocardialtissueP-selectin
proteinexpressionlevels:
Myocardial P-selection protein positive staining localized in
the cytoplasm and membrane of vascular endothelial cells.
T h el e v e l so fm o d e lg r o u pa td i ﬀerent time points were sig-
niﬁcantly greater than those of the sham operation group
(P < .05), and the levels of the Baicalin-treated group at the
pointsof3hoursand12hoursweresigniﬁcantlygreaterthan
those of the sham operation group (P < .05); the levels of the
Baicalin-treated group at the points of 3 hours and 6 hours
were signiﬁcantly less than those of the model group (P <
.01), and the levels of the Octreotide-treated group at diﬀer-
Figure 2: Model group-6h Bax × 200 (positive expression).
Figure 3: Baicalin-treated group-3h Bax × 200 (positive expres-
sion).
enttimepointsweresigniﬁcantlylessthanthoseofthemodel
group(P <.05);thelevelsoftheBaicalin-treatedgroupatthe
pointsof3hoursand12hoursweresigniﬁcantlygreaterthan
those of the Octreotide-treated group (P < .05), see Tables 3
and 4.
ComparisonofBaxproteinexpressionlevelsof
myocardialtissueinallgroups:
At3hoursand6hours,model groupwassigniﬁcantlyhigher
than sham operation group (P < .05). At 6 hours, model
groupwassigniﬁcantlyhigherthanOctreotide-treatedgroup
(P < .05). There was no marked diﬀerence among other
groups (P > .05), see Tables 5 and 6, and Figures 2–4.6 Mediators of Inﬂammation
Table 3: Changes of P-selectin protein expression in all groups.
Groups Cases Pathologic grade
− + ++ +++
Sham operation group (3h) 15 15 — — —
Sham operation group (6h) 15 15 — — —
Sham operation group (12h) 15 15 — — —
Model group (3h) 15 3 5 7 —
Model group (6h) 13 5 7 1 —
Model group (12h) 10 7 2 1 —
Baicalin-treated group (3h) 15 10 5 — —
Baicalin-treated group (6h) 15 13 2 — —
Baicalin-treated group (12h) 15 11 4 — —
Octreotide-treated group (3h) 15 15 — — —
Octreotide-treated group (6h) 15 15 — — —
Octreotide-treated group (12h) 15 15 — — —
Table 4: Comparison of P-Selectin protein expression in all groups (M(QR)).
Groups 3 hours 6 hours 12 hours
Sham operation group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Model group 1.00(1.00) 1.00(1.00) 0.00(1.00)
Baicalin-treated group 0.00(1.00) 0.00(0.00) 0.00(1.00)
Octreotide-treated group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Table 5: Changes of Bax protein expression in all groups.
Groups Cases Pathologic grade
− + ++ +++
Sham operation group (3h) 15 15 — — —
Sham operation group (6h) 15 15 — — —
Sham operation group (12h) 15 15 — — —
Model group (3h) 15 10 1 4 —
Model group (6h) 13 8 2 3 —
Model group (12h) 10 10 — — —
Baicalin-treated group (3h) 15 14 — 1 —
Baicalin-treated group (6h) 15 14 — — 1
Baicalin-treated group (12h) 15 15 — — —
Octreotide-treated group (3h) 15 14 1 — —
Octreotide-treated group (6h) 15 14 1 — —
Octreotide-treated group (12h) 15 15 — — —
Table 6: Comparison of Bax protein expression in all groups (M(QR)).
groups 3 hours 6 hours 12 hours
Sham operation group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Model group 0.00(2.00) 0.00(2.00) 0.00(0.00)
Baicalin-treated group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Octreotide-treated group 0.00(0.00) 0.00(0.00) 0.00(0.00)Zhang Xiping et al. 7
Figure 4: Baicalin-treated group-6h Bax × 200 (positive expres-
sion).
Figure 5: Baicalin-treated group-3h Bcl-2 × 200 (positive expres-
sion).
ComparisonofBcl-2proteinexpressionlevelsof
myocardialtissueinallgroups:
At6hours,Octreotide-treatedgroupwassigniﬁcantlyhigher
than sham operation group (P < .01). There was no marked
diﬀerence among other groups (P > .05), see Tables 7 and 8,
and Figure 5.
ComparisonofmyocardialtissueCaspase-3protein
expressionlevels:
Myocardial Caspase-3 protein positive staining mainly local-
ized in the cytoplasm of myocardial cells, and just a little of
it positioned in the cytoplasm of vascular endothelial cells.
Compared with the sham operation group, there were no
signiﬁcant diﬀerences in the model group at diﬀerent time
points and the Octreotide-treated group (P > .05) and the
levels of the Baicalin-treated group at the points of 6 hours
and 12 hours were signiﬁcantly greater than those of the
sham operation group (P < .05). Compared with the levels
of the model group, there were no signiﬁcant diﬀerences in
the Baicalin-treated group and the Octreotide-teated group
(P > .05), and there were also no signiﬁcant diﬀerences be-
tween the Baicalin-treated group and the Octreotide-treated
group (P > .05), see Tables 9 and 10.
Figure 6: Baicalin-treated group-3h TUNEL × 200 (negtive ex-
pression).
Comparisonofapoptoticindexofmyocardial
tissueinallgroups:
There was only one case of myocardial cell apoptosis in
Octreotide-treated group at 6 hours (apoptotic rate was
2/1000). The others were negative. No marked diﬀerence was
foundamongallgroupsatdiﬀerenttimepoints(P >.05),see
Figure 6.
Correlationanalysis:
The amylase was positively correlated with TNF-α at 3 hours
in model group (P < .01). PLA2 was positively correlated
with TNF-α at 12 hours in model group (P < .05). Amylase
was positively correlated with TNF-α at 3 hours in Baicalin-
treatedgroup(P <.05),andmeanwhileTNF-αwaspositively
correlated with PLA2 (P < .01).
5. DISCUSSION
Having important impact on SAP onset and progression,
inﬂammatory mediators can cause multiple organ injury.
Inﬂammatory mediators, such as endotoxin, PLA2,T N F - α,
MDA, ET, and NO, have signiﬁcant roles in SAP pathogen-
esis. Endotoxin can activate cardiovascular endothelial cell,
promote endothelial cell to release a great amount of cy-
tokines, lead to energy metabolism disturbance in myocar-
dial cell, myocardial lipid peroxidation, increase of oxygen
free radical, and cause damage of function and structure of
cardiovascular endothelial cell and myocardial cell [18–20].
The increase of PLA2, which is an important mediator of
pancreatic tissue and nonpancreas organ injury after pancre-
atitis occurs [21, 22], can change ultrastructure of myocar-
dial tissue [23], inhibit calcium pump of myocardial plasma
membrane, reduce calcium ion concentration in myocardial
cell, and decrease myocardial cell functions [24, 25]. The role
of NO in SAP has two aspects [26, 27]. Bulk generation of
NO can cause continuous vasodilatation, result in refractory
hypotension, lead to myocardial ischemia and anoxemia, or
participate in myocardial ischemia reperfusion injury [28].
TNF-α can damage heart function by changing intracellu-
lar Ca2+ balance, lowering myocardial contractility, and in-
ducing NO [29]. Also, MDA, which is an oxygen free radical8 Mediators of Inﬂammation
Table 7: Changes of Bcl-2 protein expression in all groups.
Groups Cases Pathologic grade
− + ++ +++
Sham operation group (3h) 15 15 — — —
Sham operation group (6h) 15 15 — — —
Sham operation group (12h) 15 15 — — —
Model group (3h) 15 13 1 1 —
Model group (6h) 13 12 1 2 —
Model group (12h) 10 10 — — —
Baicalin-treated group (3h) 15 14 — 1 —
Baicalin-treated group (6h) 15 14 — 1 —
Baicalin-treated group (12h) 15 15 — — —
Octreotide-treated group (3h) 15 8 5 2 —
Octreotide-treated group (6h) 15 11 2 1 1
Octreotide-treated group (12h) 15 15 — — —
Table 8: Comparison of Bcl-2 protein expression in all groups (M(QR)).
Groups 3 hours 6 hours 12 hours
Sham operation group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Model group 0.00(0.00) 0.00(1.00) 0.00(0.00)
Baicalin-treated group 0.00(0.00) 0.00(1.00) 0.00(0.00)
Octreotide-treated group 0.00(0.00) 0.00(1.00) 0.00(0.00)
Table 9: Changes of Caspase-3 protein expression in all groups.
Groups Cases Pathologic grade
− + ++ +++
Sham operation group (3h) 15 15 — — —
Sham operation group (6h) 15 15 — — —
Sham operation group (12h) 15 15 — — —
Model group (3h) 15 13 2 — —
Model group (6h) 13 11 2 — —
Model group (12h) 10 8 2 — —
Baicalin-treated group (3h) 15 13 2 — —
Baicalin-treated group (6h) 15 10 5 — —
Baicalin-treated group (12h) 15 10 5 — —
Octreotide-treated group (3h) 15 14 1 — —
Octreotide-treated group (6h) 15 13 2 — —
Octreotide-treated group (12h) 15 12 3 — —
Table 10: Comparison of Caspase-3 protein expression in all groups (M(QR)).
Groups 3 hours 6 hours 12 hours
Sham operation group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Model group 0.00(0.00) 0.00(0.00) 0.00(0.00)
Baicalin-treated group 0.00(0.00) 0.00(1.00) 0.00(1.00)
Octreotide-treated group 0.00(0.00) 0.00(0.00) 0.00(0.00)Zhang Xiping et al. 9
generated by body through enzymatic system and nonenzy-
matic system, can indirectly reﬂect the attack level of oxy-
gen free radical on somatocyte. SOD can eliminate superox-
ide anion free radical. SOD activity level indirectly reﬂects
body capacity of eliminating oxygen free radical. Free radi-
cal can cause glucose and lipid peroxidation, protein denat-
uration, and enzyme inactivation of cell membrane, break
DNA chain in cell, induce apoptosis, and cause heart injury
[30, 31]. Endothelin (ET) can lead to myocardial ischemia
necrosis [32, 33]and damage heart structure and function
through its vascular contractile eﬀect [34, 35]. It also can
cause heart ischemia anoxemia, or even thrombosis [36].
P-Selectin is a member of the family of cell adhesion
molecule and is expressed in most architectonic blood ves-
sels of the normal human body. However, the content is very
lowandtheexpressioncanbesigniﬁcantlyincreasedwhenin
acuteinﬂammatory[37,38].Itisalsoanimportantindicator
of inﬂammation [37, 39].
This study found that, compared with the sham opera-
tion group, P-Selectin protein expression of the model group
was signiﬁcantly upregulated, and it can be further inten-
siﬁed as the disease progressed. It is shown that P-Selectin
involved in the pathological process during the SAP heart
damage period. However, P-Selectin protein expression in
the Baicalin and Octreotide-treated groups was decreased to
varying degrees; and at the same time, the heart patholog-
ical lesion was improved. All that shows these two kinds of
medicine have some certain therapeutic eﬀects.
This experiment has fully observed the inﬂuence of
Baicalin and Octreotide on inﬂammatory mediators of SAP
rats, and discussed their heart protecting eﬀects. Study re-
sults showed that both amylase content in plasma and con-
tent of endotoxin, PLA2,N O ,T N F - α, MDA, and ET-1 in
serum were lower in Baicalin-treated group and Octreotide-
treated group than in model group, while their SOD con-
tents were higher than that of model group. The content of
endotoxin, PLA2 and ET-1 dropped signiﬁcantly in Baicalin-
treated group at all time points, and was close to that in
Octreotide-treated group. Compared with model group, the
serum NO at 3 hours and 12 hours (P < .05), serum TNF-
α at 6 hours (P < .01), and plasma amylase at 3 hours (P <
.05) dropped signiﬁcantly in Baicalin-treated group. Com-
parison of myocardial tissue P-Selectin protein expression
levels shows that the levels of the Baicalin-treated group at
the points of 3 hours and 6 hours were signiﬁcantly less than
those of the model group (P < .01), and the levels of the
Octreotide-treated group at the points of 3 hours, 6 hours,
and 12 hours were signiﬁcantly less than those of the model
group (P < .05). This experiment showed that the Bax pro-
tein expression level of myocardial tissue at 3 hours and 6
hours was higher in model group than in sham operation
group (P < .05), and model group was signiﬁcantly higher
than Octreotide-treated group at 6 hours (P < .05). The Bcl-
2 protein expression level of myocardial tissue at 6 hours
was signiﬁcantly higher in Octreotide-treated group than in
sham operation group (P < .01). The levels of myocardial
tissue Caspase-3 protein expression in the Baicalin-treated
group at the points of 6 hours and 12 hours were signiﬁ-
cantly greater than those of the sham operation group (P <
.05). There was only a case of myocardial cell apoptosis in
Octreotide-treated group at 6 hours, and other groups were
negative. The NF-κB protein expression of myocardial tissue
was negative in all groups. In addition, the NF-κBp r o t e i n
expression was negative in all groups at diﬀerent time points,
indicating no NF-κB expression in heart. Therefore, NF-κB
cannot directly act on heart. Bax and Bcl-2, respectively, can
induce and inhibit apoptosis.
Caspase-3isoneoftheimportantproteaseswhichcanin-
duceapoptosisandisalsotheﬁnaleﬀectfactoroftheCaspase
cascade eﬀect which is involved in apoptosis, and moreover
itisatthecorepositionintheprocessofcuttingproteasecas-
cade.Caspase-3isamarkerofapoptosisanditisalsotheper-
former of apoptosis. It can destroy a variety of protease com-
plex in cells with the digestive way, activate intranuclear nu-
cleasetocausetheDNAschizolysisformtheDNAfragments,
undermine cell calcium pump function, lead to the situation
of intracellular calcium overload, and so on [40, 41]. Inhibit-
ing Caspase-3 activity can reduce the occurrence possibility
of apoptosis [42].
In this study, we found that the levels of myocardial
tissue Caspase-3 protein expression in the Baicalin-treated
group were signiﬁcantly greater than those of the sham
operation group. Compared with the model group, there
were no signiﬁcant diﬀerences in the Baicalin-treated group
and the Octreotide-treated group, and there was no signif-
icant diﬀerence between the Baicalin-treated group and the
Octreotide-treatedgroup.ItisshownthattheroleofBaicalin
and Octreotide inducing myocardial apoptosis may be irrel-
evant to Caspase-3 in SAP. The results of this experiment
showed apoptosis had limited and harmful eﬀects in heart
injury.
The experiment showed us that Baicalin and Octreotide
can eﬀectively lower the level of inﬂammatory mediators,
andhaveprotectingeﬀectsonheartsofSAPrats.Inaddition,
thisexperimenthasappliedtissuemicroarrays,whoseadvan-
tages include high throughput, multiple samples, cost and
time saving, low error, convenience for experimental control
design, capability to combine other biotechnologies, and ex-
tensive applications to greatly lower study cost, improve the
eﬃciency of pathohistological study, and achieve satisfactory
results. We have not seen this method applied in pancreas
pathological study till now. This article has reported its ap-
plication for the ﬁrst time. We believe it is worth populariza-
tion.
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